anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Participants in the intervention (peppermint oil) arm will receive soft gels of enteric-coated peppermint oil (0.2mL=200mg). The enteric coated peppermint oil soft gel utilized in this study is Peptogest Peppermint Oil from Schwabe North America (Nature's Way Brand).
Transfer RNA (tRNA)-derived small RNAs (tsRNAs) are a new type of non-coding RNAs (ncRNAs) produced by the specific cleavage of precursor or mature tRNAs. tsRNAs are involved in various basic biological processes such as epigenetic, transcriptional, post-transcriptional, and translation regulation, thereby affecting the occurrence and development of various human diseases, including cancers. Recent studies have shown that tsRNAs play an important role in tumorigenesis by regulating biological behaviors such as malignant proliferation, invasion and metastasis, angiogenesis, immune response, tumor resistance, and tumor metabolism reprogramming. These may be new potential targets for tumor treatment. Furthermore, tsRNAs can exist abundantly and stably in various bodily fluids (e.g., blood, serum, and urine) in the form of free or encapsulated extracellular vesicles, thereby affecting intercellular communication in the tumor microenvironment (TME). Meanwhile, their abnormal expression is closely related to the clinicopathological features of tumor patients, such as tumor staging, lymph node metastasis, and poor prognosis of tumor patients; thus, tsRNAs can be served as a novel type of liquid biopsy biomarker. This review summarizes the discovery, production, and expression of tsRNAs and analyzes their molecular mechanisms in tumor development and potential applications in tumor therapy, which may provide new strategies for early diagnosis and targeted therapy of tumors.
Escitalopram 10mg once daily to be started for 1 week. Dose will then be titrated to 20mg once daily and the patients followed for a total of 12 weeks.
In this study, patients with CF due to a nonsense mutation will be treated with a new investigational drug called PTC124. Evaluation procedures (history, physical examination, blood and urine tests to assess organ function, electrocardiogram (ECG), chest x-ray, and CF-specific tests) to determine if a patient qualifies for the study will be performed within 21 days prior to the start of treatment. Eligible patients who elect to enroll in the study will then participate in two 28-day treatment and follow-up periods (56 days total). Within the first 28-day period, PTC124 treatment will be taken 3 times per day with meals for 14 days at doses of 4 mg/kg (breakfast), 4 mg/kg (lunch) and 8 mg/kg (dinner); there will then be an interval of 14 days without treatment. Within the second 28-day period, PTC124 treatment will be taken 3 times per day with meals for 14 days at doses of 10 mg/kg (breakfast), 10 mg/kg (lunch) and 20 mg/kg (dinner); there will then be an interval of 14 days without treatment. There will be a 2-night stay at the clinical research center at the beginning and at the end of each 14 days of PTC124 treatment, which means that there will be four 2-night stays at the clinical research center during the study. During the study, PTC124 efficacy, safety, and pharmacokinetics will be evaluated periodically with measurement of transepithelial potential difference (TEPD), nasal mucosal brushing to assess for cellular CFTR mRNA and protein, medical history, physical examinations, blood tests, urinalysis, ECGs, chest x-ray, and pulmonary function tests.
Reactions suggestive of hypersensitivity associated with administration of dobutamine including skin rash, fever, eosinophilia, and bronchospasm, have been reported occasionally.

Dobutamine Hydrochloride in 5% Dextrose Injection contains sodium bisulfite, a sulfite that may cause allergic-type reactions, including anaphylactic symptoms and life-threatening or less severe asthmatic episodes, in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people.

Solutions containing dextrose should not be administered through the same administration set as blood, as this may result in pseudoagglutination or hemolysis.

The intravenous administration of solutions may cause fluid overloading resulting in dilution of serum electrolyte concentrations, overhydration, congested states or pulmonary edema. The risk of dilutional states is inversely proportional to the electrolyte concentrations of the injections. The risk of solute overload causing congested states with peripheral and pulmonary edema is directly proportional to the electrolyte concentration of the injections.

Excess administration of potassium-free solutions may result in significant hypokalemia.
* NEMLUVIO is administered by subcutaneous injection.
  * NEMLUVIO is intended for use under the guidance of a healthcare provider. Prior to the first injection, provide patients and/or caregivers with proper training on the preparation and administration of NEMLUVIO. Patients may self-inject NEMLUVIO after receiving training on subcutaneous injection techniques. 
  * For the initial dose, administer each of the two NEMLUVIO injections at different injection sites. 
  * Administer subcutaneous injection into the front upper thighs or abdomen except for the 2 inches (5 cm) around the navel. Injection in upper arm should only be performed by a caregiver or healthcare professional. 
  * Alternate the injection site with each injection. Do not inject NEMLUVIO into skin that is tender, inflamed, swollen, damaged or has bruises or scars or open wounds. 
  * Refer to the Instructions for Use for complete administration instructions with illustrations [see Instructions for Use].
Patients will undergo EEG recordings at rest and while performing the set of motor and cognitive tasks and BNA analysis. Additionally patients will be rated using MoCA, FAB, Verbal Fluency, - Beck Depression Inventory, PDQ-39, PD sleep scale (PDSS), MDS-UPDRS.SF-EMG and KinesiaOne and motion sensor assessment for tremor.
INTRODUCTION: Olfactory impairment is one of the cardinal symptoms of chronic rhinosinusitis with nasal polyps (CRSwNP). However, the effect of currently available therapeutic options on the recovery of the sense of smell is not well defined. The aim of this systematic review was to compile evidence on the impact of medical, surgical, and biological treatment on olfactory outcomes in patients with CRSwNP.
METHODS: This review was conducted by 2 reviewers according to the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines. The quality of evidence of all the studies included in the qualitative synthesis was evaluated using the Critical Appraisal Skills Programme (CASP).
RESULTS: Forty-four studies were included in the qualitative synthesis. These assessed sinonasal surgery (n=23), biologics (n=15), and conventional medical treatment (n=6). The methodological quality was moderate-to-high in most. Overall, significant improvements in the sense of smell were detected with all the interventions analyzed and measured using an objective tool, a subjective tool, or both. However, most studies used different outcome measures, thus hindering comparisons between interventions, and data on clinically relevant changes were missing.
CONCLUSION: Oral corticosteroids, biologics, and sinonasal surgery improve the olfactory impairment associated with CRSwNP. However, the heterogeneous nature of existing studies does not allow accurate comparisons.
Biventricular (BiV) pacing is an established treatment of symptomatic heart failure patients with severely reduced left ventricular ejection fraction (HFrEF) and wide QRS due to bundle branch block (BBB) on a 12-lead ECG. BiV pacing is normally achieved with an endocardial pacing lead in the right ventricle and an epicardial lead over the left ventricle situated in a coronary vein. BiV pacing does not correct the BBB but corrects the mechanical dyssynchrony that is a consequence of the BBB. It has been shown to work best on patients with "true" left bundle branch block (LBBB) where the block is due to disease within the conduction system (and not for example left ventricular hypertrophy or scars). Even if the patient is an ideal candidate for BiV pacing it can sometimes be difficult to achieve the best mechanical resynchronization because of anatomic difficulties, high pacing thresholds or phrenic nerve capture.

In recent years it has been demonstrated that the level of block in true LBBB is often within the bundle of HIS and it is possible in many cases to place a pacing lead distally to the site of block and get capture of both right and left bundles thereby "correcting" the BBB and achieve a normal or near-normal QRS complex. If the conduction system is intact distal to the block this mode of pacing leads to complete resynchronization of the ventricles. HIS-pacing can be achieved as either selective HIS-capture where it is only the conduction system that is paced leading to a narrow QRS complex. However, mostly it is achieved with non-selective HIS-capture where both the septal myocardium close to the pacing site and the His-bundle is captured. This leads to a QRS resembling the QRS achieved by selective HIS-capture but preceded by a delta-wave-like deflection which broadens the QRS complex. Since it is only a small part of the septum that is captured early this does not influence the resynchronization of the heart. In some patients HIS-pacing cannot be achieved due to anatomical difficulties that hinders reaching the HIS bundle with the present tools available. In others it is not possible to come distal to the block and recruiting both the left and the right bundle branch.

There is to date no randomized studies between HIS-bundle pacing and BiV pacing in HFrEF patients with LBBB but there are several case reports and retrospective data on successful HIS-bundle pacing in these patients. The present study will randomize 50 patients in a single centre to HIS-pacing or BiV pacing to determine to which extent it is possible to achieve normalization or near-normalization of the QRS with HIS-bundle pacing and what this translates to with regard to symptom relieve, walking distance, echocardiographic measures and N-terminal pro B-type natriuretic peptide (NT-proBNP) levels as compared to BiV pacing.
BACKGROUND: Coronary anomalies are those conditions characterized by the abnormal origin or course of the epicardial arteries. This generates challenges at the time of diagnosis by catheterization, which is why it is important that the cardiologist is related to these variations. The origin of the left coronary artery in the right sinus of Valsalva has a low incidence. It is reported the case of a patient with myocardial infarction who presented this anomaly with total thrombotic occlusion.
CLINICAL CASE: 69-year-old man who presented myocardial infarction with ST segment elevation in the anteroseptal region. The catheterization reported left coronary artery with anterior origin and the right coronary sinus. The anterior descending artery presented thrombotic occlusion, which is why a stent was placed successfully. Subsequently, the tomography of the coronary arteries confirmed the anomalous origin of the left coronary artery from the right sinus of Valsalva, with a lateral and anterior course to the right ventricle.
CONCLUSIONS: Patients with anomalous origin of the coronary arteries are exposed to greater events of ischemia and sudden death. However, some patients present with no previous history of acute coronary syndrome associated with thrombotic occlusion, which can represent a diagnostic challenge at the time of catheterization and coronary intervention due to the anatomic variability they may present.
PURPOSE: A composition containing a Chrysanthemum zawadskii extract is provided to suppress pancreatic beta cell damage and to prevent glucotoxicity. CONSTITUTION: A composition for preventing and treating diabetic disorders contains a Chrysanthemum zawadskii extract as an active ingredient. The extract is prepared using water or a low carbon number alcohol of C1-C4. The low carbon number alcohol is ethanol. The extract suppresses pancreatic beta cell damage to quickly recover damaged pancreatic beta cells. The extract also suppresses pancreatic beta cell apoptosis. The composition further contains a pharmaceutically acceptable carrier. The carrier is a diluent, a filler, a binder, a disintegrant, a disintegration inhibitor, an absorption promoting agent, a wetting agent, a lubricant, a suspension, a surfactant, or a flavoring agent. [Reference numerals] (AA) dRib(30mM)+Chrysanthemum zawadskii; (BB) Chrysanthemum zawadskii
The disclosed technology includes a system for modeling progression of lifetime healthcare expenses, including healthcare events resulting in an out-of-pocket expenditure per a given healthcare plan, wherein each healthcare event is associated with a group of healthcare events. Each group of healthcare events is associated with different sets of certainty with different groups of individuals. A central computing device communicates with healthcare event data generation sources to obtain the healthcare event data. A static database module stores the healthcare event data in hierarchical layered graphs. A dynamic database module dynamically generates data that depicts different future expenditures over a life span based on the healthcare event data in the static database module. A computer modeling module generates the most likely set of future expenditures using the different future expenditures data in the dynamic database module.
Participants will be provided with 3 servings of a placebo rehydration supplement for consumption after the completion of the dehydrated heat stress intervention. Participants will be instructed to consume each serving in a time-dependent manner over the 24-hour period after dismissal from the laboratory after completion of the Intervention session.
Temozolomide is given at 150 mg/m2/day x 5 days orally and combined with irinotecan 50 mg/m2/day x 5 days as one hour infusions. Two of these cycles are followed by the common radiation - four cycle chemotherapy protocol.
PROBLEM TO BE SOLVED: To obtain an antifungal and insecticidal product for external use, free from irritation, extremely low in development of allergic symptom and applicable to veterinary medicines by including copper oleate in a specific state as an active ingredient. SOLUTION: This product contains copper oleate in a manner dispersed as aqueous colloid. The product can be utilized as shampoo, lotion or cream. For example, shampoo is obtained by formulating 0.1-2 wt. 96 of the active ingredient with 20-40wt.% of 25% aqueous solution of sodium lauryl ether sulfate as an aqueous colloidal dispersion, 1-3wt.% coconut oil fatty acid diethanol amide and the balance of distilled water. The product has excellent characteristics on beauty and further, the product is especially effective against louse, acarid, etc.
PCT No. PCT/CA93/00062 Sec. 371 Date Aug. 19, 1994 Sec. 102(e) Date Aug. 19, 1994 PCT Filed Feb. 16, 1993 PCT Pub. No. WO93/16733 PCT Pub. Date Sep. 2, 1993A pharmaceutical composition comprising a plurality of effective non-toxic dosage amounts of a composition for topical administration to the site of pathology and/or trauma of skin and/or exposed tissue of a human patient in need of treatment suffering from a disease or condition, each such dosage amount comprising a therapeautically effective non-toxic (to the patient) dosage amount of a drug for the treatment of the disease and/or condition of the skin and/or exposed tissue at the site of the pathology and/or trauma and an effective non-toxic dosage amount of hyaluronic acid and/or salts thereof and/or homologues, analogues, derivatives, complexes, esters, fragments, and/or sub-units of hyaluronic acid to transport (to facilitate or cause the transport of) the drug to the site of the pathology and/or trauma of the disease or condition.
Group 1. Dose: 10 7.0-7.49 EID 50/dose. Both first and second administration by the intramuscular route, separated by 21 days.
BACKGROUND: Papillary thyroid carcinoma (PTC) is the most common type of thyroid cancer. In rare instances, PTC has metastasized to the retropharyngeal and parapharyngeal nodes. This is hypothesized to occur due to an aberrant lymphatic channel or via retrograde lymphatic flow following previous neck dissection.
METHODS: A literature search was conducted with keywords "parapharyngeal," "retropharyngeal," and "papillary thyroid carcinoma."
RESULTS: 46 articles were identified for a total of 135 cases. The most common presenting symptom was lymphadenopathy followed by pharyngeal mass and dyspnea. 38.03 % of patients were asymptomatic. Of cases including initial treatment history, 94.44 % had a history of neck dissection. The transcervical approach was the most utilized to resect the tumors, although in recent years trans-oral robotic surgery (TORS) has also been used.
CONCLUSION: PTC metastatic to the retropharyngeal and parapharyngeal nodes is a rare occurrence that can be difficult to diagnose due its indolent nature.
The primary objective of this study is to determine whether testosterone replacement in older men, who have low testosterone levels and mild to moderate physical impairment, will increase their maximal voluntary muscle strength of major upper and lower extremity muscle groups. The second objective is to determine whether testosterone replacement will improve the power of knee extension, physical performance tests, the level of physical activity (measured by 3D accelerometer), self-reported disability, exercise tolerance and mobility. The third objective is to determine whether testosterone supplementation improves fatigue, affect, and overall sense of well being in older men with low testosterone levels. A fourth objective is to define the Minimum Clinically Important Differences in physical measures perceived by the participants (MCID).

Participant involvement will require 15-17 clinic visits over 28 weeks. Five to 7 of these visits are for physical testing, including body composition, muscle performance, and physical function. Throughout the study, hormone measurements will be obtained.
BACKGROUND Paroxysmal third-degree atrioventricular block (AVB) can exhibit a vast array of symptoms, but commonly, paroxysmal AVB leads to presyncope, syncope, or possibly sudden cardiac death. We present a rare case of pause-dependent paroxysmal AVB that was triggered by a premature atrial contraction. CASE REPORT A 65-year-old man with frequent episodes of presyncope and syncope for 3 weeks was admitted to our hospital for further diagnosis. A resting 12-lead electrocardiogram showed an incomplete right bundle branch block, and a 24-h Holter recording showed multiple episodes of third-degree AVB. Intracardiac tracing revealed that the block site was distal, at the infra-His-Purkinje system. CONCLUSIONS This case highlights a rare case of pause-dependent paroxysmal AVB that was triggered by a premature atrial contraction. This type of AVB is an abrupt, unexpected, repetitive block of atrial impulses as they propagate to the ventricles. It is relatively rare, and due to its transient nature, it is often under recognized and can lead to sudden cardiac death.
Nasal allergen challenge (NAC) is a useful tool in the investigation of allergic rhinitis, including grass pollen-induced seasonal allergic rhinitis (hay fever). We have experience in using NAC to investigate the clinical and immunological effects of allergen exposure and in using NAC as a surrogate outcome to assess the efficacy of treatments for allergic rhinitis. The procedure is safe and well tolerated. In order for NAC to be a valid tool, it is essential that the allergen extracts used are standardised in terms of concentration and stability in solution. We have previously used an extract of Timothy Grass (Phleum pratense) pollen, Aquagen (ALK-Abello, Denmark). Aquagen is supplied as a dry powder, to be reconstituted prior to use by dissolving in an albumin-based diluent. Unfortunately, Aquagen production has been discontinued, but the identical allergen is now available as Timothy Grass lyophilisate tablet, Grazax (ALK-Abello), an approved and licensed product for treatment of severe seasonal allergic rhinitis. Grazax consists of purified, freeze-dried Timothy Grass pollen extract, plus only three excipients, gelatin (from fish), mannitol and sodium hydroxide. Preliminary investigations have shown that Grazax tablets can be dissolved in saline to produce identical concentrations of allergen to Aquagen, with the same stability profile in vitro. We anticipate therefore, that the clinical effect when used for nasal allergen challenges would be equivalent to the use of Aquagen for a given allergen concentration. In this study we intend to confirm that nasal symptoms produced during the NAC with either Aquagen or Grazax will be equivalent. We will recruit volunteers with grass pollen-induced hay fever to undergo NAC with each allergen source, sequentially. In an open, randomised-order, cross-over study. The primary outcome will be patient-reported nasal symptoms (according to a standardised scoring system) in the 60 minutes after each nasal challenge.
Methods and systems for automatically communicating information (e.g., patient information, flow rate, etc. . . . ) between a non-MRI compatible IV pump and a MRI compatible IV pump are described herein. Such methods and systems prevent human error from affecting the reprogramming of the IV pumps. Furthermore, automatically clamping infusion lines when a new line is added and locked in also reduces possible human error by removing the need for user input during this process.
A personal medical status device attaches to a medical testing kit to receive a test result and status for a medical condition of a user. The personal medical status device authenticates the user to provide the status of the condition using a fingerprint scanner as well as other methods. A clock display provides time related information based on the latest test result. The clock display can show the time from the previous test or time until the next test. A test result display provides a visual indicator of the status of the user without compromising privacy. A proprietary dock allows connection to the medical testing kit while being tamper-proof.
There were 24.5 million physician visits for otitis media (OM) in 1990 with estimated treatment and indirect costs of $5 billion. Because of its major public health impact and the troubling increase in antibiotic resistant organisms, vaccine strategies to prevent OM are being tested. We previously proposed an efficacy study to determine if immunization with pneumococcal vaccine during pregnancy protects offspring against early infant OM, which is an important predictor for recurrent and chronic OM. Recent data from an efficacy trial in California demonstrated that infants immunized with 7-valent pneumococcal conjugate vaccine (PNCRM7) at 2, 4, 6 and 12 - 15 months were protected against invasive pneumococcal disease after 7 months of age. Since licensure of this vaccine, questions have been raised about whether maternal immunization with a pneumococcal vaccine during pregnancy suppresses active antibody production in offspring who are immunized with 7-valent pneumococcal conjugate vaccine (PNCRM7). The main objective of this study is to investigate that question. We will also evaluate vaccine safety, immunogenicity, and fetal antibody transfer among women who receive 9-valent pneumococcal conjugate vaccine (PNCRM9) at 30 - 35 weeks of pregnancy, determine persistence of maternal and infant antibody 13 months after birth, evaluate opsonic activity of maternal and infant antibody, and determine the relationship between breast milk and serum antibody in lactating women.